ClinicalTrials.gg
RecruitingNCT07426484Updated Aug 11, 2026

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

A Phase 4 interventional study of Cosibelimab and Prednisone in Cutaneous Squamous Cell Carcinoma and Skin Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Dana-Farber Cancer Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Skin Neoplasms with a site in United States — 64 open to participants now, 98 under way, 7 of them phase 3. Skin Neoplasms · United States.

Planned enrollment
110th of 290
80 · median 44
Started
2026
with 16 others
Phase 4
11 of 381
5 open now
Primary completion
2030-12
later than 93 of 96 live
Registered
368th of 381
by date

Among the 381 studies in Skin Neoplasms with a site in United States, this one is the 110th largest by planned enrollment of the 290 interventional ones that give a count, is one of 17 that started in 2026, is one of 11 in phase 4, reaches primary completion later than 93 of the 96 other live ones, and was the 368th registered.

Skin Neoplasms

606 studies on the registry are indexed under Skin Neoplasms; 127 are open to participants now.

Browse Skin Neoplasms studies →

Open to participants now

64 of the 381 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Skin Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).

The name of the drug involved in this research study is:

-cosibelimab (a type of an anti-PD-L1 antibody)

Read the detailed description

This is a Phase IV, multi-site, multi-cohort, open-label clinical trial investigating the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). Checkpoint Therapeutics is supporting this research study by providing the study drug, cosibelimab.

Participants will be enrolled into one of two study groups: Group A or Group B.

Cosibelimab is FDA-approved for the treatment of advanced cutaneous squamous cell carcinoma

The research study procedures include screening for eligibility, in-clinic visits, blood tests, urine tests, Computerized Tomography (CT) scans, or Positron Emission (PET) scans, electrocardiograms (ECGs), Tumor biopsies and aspirations.

It is expected that about 80 people will take part in this research study.

03

Conditions studied

  • Cutaneous Squamous Cell Carcinoma
  • Skin Cancer

Keywords

  • Advanced Cutaneous Squamous Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma
  • Skin Cancer
  • Kidney Transplant Recipient
  • Chronic lymphocytic leukemia (CLL)
  • Myeloma
  • Waldenstrom macroglobulinemia
  • Solid Organ Transplant Recipient
  • Immunosuppressed
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COHORT A: Participant must have a history of kidney transplant (at least 6 months prior to enrollment). (A history of more than one kidney transplantation is permitted.)
  • COHORT B: Participant must have a diagnosis of a hematologic , including chronic myeloproliferative neoplasm (CMN) or an indolent non-Hodgkin's lymphoma (NHL), or multiple myeloma (MM).
  • Examples of indolent non-Hodgkin's lymphomas (NHL), including but not limited to:

    • Chronic lymphocytic leukemia (CLL)
    • Small cell lymphocytic lymphoma (SLL)
    • Follicular lymphoma (FL)
    • Lymphoplasmacytic lymphoma
    • Waldenström macroglobulinemia
    • Marginal zone lymphoma
    • Mantle cell lymphoma, indolent variety
    • Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
  • Examples of chronic myeloproliferative neoplasms (CMN), including but not limited to:

    • Chronic myelogenous leukemia (CML)
    • Polycythemia vera (PV)
    • Primary myelofibrosis
    • Essential thrombocythemia (ET)
    • Chronic neutrophilic leukemia
    • Chronic eosinophilic leukemia
  • Examples of myeloma, including but not limited to:

    • Multiple myeloma (MM)
    • Smoldering myeloma
  • Participants must have or cytologically confirmed diagnosis of cutaneous squamous cell carcinoma (CSCC).
  • Note: Mixed histology is acceptable (e.g. basosquamous, squamous cell carcinoma with adnexal differentiation), and other histologic variants (sarcomatoid carcinoma, spindle cell carcinoma, poorly differentiated carcinoma with squamous features).
  • Participant must have CSCC that is not amenable to surgery or radiation therapy, or recurrent despite prior surgery or radiation therapy, including locally advanced unresectable CSCC for which local therapy (surgery and/or radiation therapy) is not recommended. This includes CSCC occurring in patients who are not surgical candidates due to comorbidities and patients who refuse surgery (due to concerns about morbidity, disfigurement, etc).
  • Participants must have as per PET Response Criteria in Solid Tumors version
  • (PERCIST 1.0),46 defined as any tumor (of any size) whose SUV lean (SUL) peak is greater than 1.5 times the mean SUL in the liver + 2 times its standard deviation. Mean SUL in the liver is measured in a 3-cm diameter spherical volume of interest (VOI), which is a measurement of the SUV background.
  • Age ≥18 years. Because no dosing or adverse event data are currently available on the use of cosibelimab in participants \<18 years of age, children are excluded from this study.
  • performance status 0-2 (see Appendix A for definitions of this and Performance Status).
  • Participants must meet the following organ and marrow function as defined below:

    • ≥1.0 K/mcL
    • ≥30 K/mcL
    • Total ≤ 1.5 institutional (ULN), except subjects with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL
    • (SGOT) ≤ 2.5 × institutional ULN
    • ALT(SGPT) ≤ 2.5 × institutional ULN
    • Adequate renal function, defined as defined as estimated (eGFR) ≥ 30 mL/min
    • Serum creatinine ≤ 3.0 x institutional ULN or ≤ 3.0 x baseline (grade ≤ 2 per )
  • Participants with new or progressive (active brain metastases) or are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
  • and PD-L1 immune checkpoint antibodies are classified as pregnancy class D. For this reason, and because other therapeutic agents used in this trial are potentially teratogenic, women of (WOCBP) and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and 120 days after completion of cosibelimab administration. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 120 days after completion of cosibelimab administration.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment within the past 12 months with any of the following classes of drugs: inhibitors, anti-PD-L1 inhibitors, or anti-CTLA-4 inhibitors.
  • Prior treatment within the past 6 months with CAR-T cell therapies, other cellular therapies, or multiagent cytotoxic chemotherapy regimens (e.g. R-CHOP). (Bispecific antibodies and EGFR- targeted therapies are permitted without a .)
  • Participants who have adverse events due to prior anti-cancer therapy not recovered to Grade 1 or less, with the exception of alopecia, sensory neuropathy, and cytopenias.
  • Active disease that is currently requiring systemic treatment with prednisone >10mg daily (or equivalent), anti-CD20 antibodies, intravenous immunoglobulin (IVIG) or JAK inhibitors (ruxolitinib, tofacitinib, upadacitinib, etc).
  • Severe interstitial lung disease (ILD), or a history of pneumonitis that has required oral or IV steroids in the past 5 years.
  • Participants who are receiving any other agents for cancer within 2 weeks of study enrollment.
  • Participants who have uncontrolled, symptomatic infections, or infections requiring systemic antibiotics (prophylactic antimicrobials are permitted).
  • Participants who have uncontrolled or unstable (or other CNS metastases) for whom systemic steroids are required. These patients are excluded because steroids may interfere with the effectiveness of immune checkpoint therapy.
  • Uncontrolled or significant cardiovascular disease.
  • Current need for dialysis (hemodialysis or peritoneal dialysis).
  • History of stem cell transplant or bone marrow transplant
  • Psychiatric illness or social situation that would preclude study compliance.
  • Pregnant and breastfeeding women are excluded from this study because cosibelimab is classified as pregnancy class D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cosibelimab, breastfeeding should be discontinued if the mother is treated with cosibelimab.
  • Participants with a prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the study drug are excluded.
  • COHORT A ONLY:

    • History of organ transplant other than kidney, including a heart, lung, or liver transplant, etc, with the exception of cornea transplantation. Cornea transplant is allowed if participant is not taking systemic medication expressly for the purpose of corneal allograft.
    • History of severe allergic reaction attributed to sirolimus or everolimus, or other absolute to mTOR inhibitor, as determined by the treating physician.
  • COHORT B ONLY: History of any solid organ transplant, with the exception of cornea transplantation. Cornea transplant is allowed if participant is not taking systemic immunosuppressive medication expressly for the purpose of corneal allograft.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Cohort A: Cosibelimab + Standard of Care Immunosuppressive Regimen

    40 Kidney transplant recipients with advanced CSCC will be enrolled and will complete the following- * Baseline visit * Cycle 1 through Cycle 17 (21-day cycle) * Day 1: Predetermined dose Cosibelimab 1x daily. * Day 1 through 21: pre-determined dose of Prednisone 1X daily * Day 1 through 21: determined dose of sirolimus or everolimus 1X daily * Follow-up every three months * Long-term follow-up

    Drug: Cosibelimab · Drug: Prednisone · Drug: Sirolimus · Drug: Everolimus

  • Experimental
    Cohort B: Cosibelimab

    40 Participants with co-diagnosis of hematologic malignancy/myeloproliferative disorder and advanced CSCC will be enrolled and will complete- * Baseline visit * Cycle 1 through Cycle 17 (21-day cycle) --Day 1: Predetermined dose Cosibelimab 1x daily. * Follow-up every three months * Long-term follow-up

    Drug: Cosibelimab

Interventions

  • Anti-PD-L1 antibody, single dose vials, via intravenous (into the vein) infusion per protocol

    Also known as: CK-301, Cosibelimab-ipdl, UNLOXCYT

  • Corticosteroid, per standard of care

  • mTOR Inhibitor, per standard of care

  • mTOR Inhibitor, per standard of care

06

What researchers measure

Primary outcomes

  1. Best Overall Response Rate (BORR)

    BORR is defined as the proportion of participants whose best overall responses are complete metabolic response (CMR) and partial metabolic response (PMR). Per PERCIST 1.0 for target lesions, CMR is visual disappearance of all metabolically active tumor, and PMR is at least a 30% decrease in SUL peak (minimum 0.8-unit decrease) in the lesion with greatest uptake, not necessarily the same lesion.

    Time frame: Up to 102 weeks.

Secondary outcomes

  1. Treatment-Emergent Adverse Events (TEAEs) Rate

    TEAEs rate is defined as the proportion of participants who experience one or more adverse events that emerge or worsen after the initiation of study treatment.

    Time frame: Treatment duration is up to 51 weeks, and adverse events will be collected through 30 days following the end of treatment.

  2. Immune-related Adverse Events (AE) Rate

    The immune-related AE rate is defined as the proportion of participants who experience at least one adverse event considered by the investigator to be immune-related during the study treatment period.

    Time frame: Treatment duration is up to 51 weeks, and adverse events will be collected through 30 days following the end of treatment.

  3. Allograft Rejection and Allograft Loss Rate in Cohort A

    Allograft rejection loss rate is defined as the proportion of participants in Cohort A who experience allograft rejection or allograft loss, as determined by elevated serum creatinine, urine protein levels, donor-derived cell-free DNA (dd-cfDNA), renal biopsy findings, or the need for renal replacement therapy.

    Time frame: Up to 51 weeks.

  4. Median Progression-Free Survival (PFS)

    PFS is defined as the time from registration to the earlier of progressive metabolic disease (PMD), as defined by PERCIST 1.1, or death from any cause. PFS will be estimated using the Kaplan-Meier method. Participants who are alive without documented disease progression at the time of analysis will be censored at the date of their last disease evaluation.

    Time frame: Tumor assessments will be performed before Cycle 3, 5 Day 1 (28-day cycles) and every 4 cycles through Cycle 17. Follow-up assessments will occur on Cycle 18, 21, 29, and 33 Day 1.

  5. Duration of Response (DOR)

    DOR, defined according to PERCIST 1.1, is measured using the Kaplan-Meier method from the first documentation of complete metabolic response (CMR) or partial metabolic response (PMR), whichever occurs first, to the earliest date of objectively documented recurrent or progressive metabolic disease (PMD), using the lowest recorded measurements since treatment initiation as the reference, or death from any cause. Participants without documented events will be censored at the date of their last disease evaluation.

    Time frame: 2 years

  6. Median Overall Survival (OS)

    OS based on Kaplan-Meier method is defined as time from date of first dose until the date of death due to any cause. Participants are censored as date last known alive.

    Time frame: Up to 147 weeks

  7. Median Disease Specific Survival (DSS)

    DSS based on Kaplan-Meier method is defined as the time from study enrollment to death specifically due to advanced cutaneous squamous cell carcinoma (CSCC). Deaths from other causes are censored at the time of occurrence.

    Time frame: Up to 102 weeks.

  8. Median Circulating Tumor DNA (ctDNA) Levels

    ctDNA will be assessed from plasma using a personalized mPCR-NGS-based assay (Signatera™). ctDNA levels will be quantified as mean tumor molecules per milliliter of plasma (MTM/mL).

    Time frame: Up to 102 weeks.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2030, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 23, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Dec 15, 2030
CompletionEst.
Dec 15, 2032
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07426484
Responsible party
Ann W. Silk, MD MS (Senior Physician/Medical Oncologist, Dana-Farber Cancer Institute) — Principal investigator
First posted
Feb 23, 2026
Start date
Apr 23, 2026
Primary completion
Dec 15, 2030 (estimated)
Completion
Dec 15, 2032 (estimated)
Last update
Aug 11, 2026

Study contacts

Ann Silk, MD
Contact
Ann_Silk@dfci.harvard.edu
617-632-6836
Ann Silk, MD
Contact
CosiMaster@dfci.harvard.edu
617-632-6836
Ann Silk, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cosibelimab

Start the discussion